Biogen Idec, Inc. (Massachusetts) and Swedish Orphan Biovitrum Present New Data From the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE™

Published: Jul 08, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WESTON, Mass. and STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE* for hemophilia A. Five platform and oral presentations at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress in Amsterdam, The Netherlands, highlight the new FVIII candidate’s potential to reduce the number of intravenous injections people with hemophilia A require, its efficacy in controlling bleeding during and after surgery, and its efficacy in treating acute bleeding episodes.

Help employers find you! Check out all the jobs and post your resume.

Back to news